# Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)

> **NCT04558866** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Latin American Cooperative Oncology Group** · enrollment: 51 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Testosterone Cypionate
- **DRUG:** Darolutamide

## Key facts

- **NCT ID:** NCT04558866
- **Lead sponsor:** Latin American Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-09
- **Primary completion:** 2024-03-15
- **Final completion:** 2026-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04558866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04558866, "Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04558866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*